ERBB2 and ductal breast carcinoma in situ: The investigation of HER2 patients for cardiotoxicity is relevant to their prognosis, and although HER2 status in invasive cancer is established in a patient’s prognosis, its presence in ductal carcinoma in situ (DCIS) is less so, with current guidance suggesting against HER2 testing in these patients [68].